Vaccine Information

Where?
Lititz Apothecary
100 East Main St.,
Lititz, PA 17543

When?
General Availability Open!

How?
Register Online
Bring your Form ID from your confirmation email!

Optional: Fill out the COVID 19 vaccine consent form ahead of time:

Online Vaccine Registration


Current Updates

CDC’s updated recommendations (June 18th, 2022)

  • Added guidance for a three dose primary series of the Pfizer-BioNTech COVID-19 vaccine (3 microgram each dose (maroon cap and label) for infants and children 6 months through 4 years of age) (two doses separated by 21 days (3 weeks), followed by a third dose at least 8 weeks after the second dose).
  • Added guidance for a two dose primary series of the Moderna pediatric COVID-19 vaccine (25-microgram each dose) for infants and children 6 months through 5 years of age (two doses separated by 28 days).
  • CDC will consider use of the Moderna COVID-19 vaccine in children 6 – 17 years old at its June 21-23, 2022, meeting.

CDC’s updated recommendations (May 19th, 2022)

  • Added guidance that people ages 5 years and older may receive a booster dose of pediatric Pfizer vaccine after 5 months of completing their primary series.
  • Added guidance that people ages 12 years and older who are moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
  • Added guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
  • Added guidance that people ages 18–49 years who are not moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose.
  • Further clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) and myocarditis.